Sarepta Therapeutics (SRPT) Gross Margin (2016 - 2025)
Historic Gross Margin for Sarepta Therapeutics (SRPT) over the last 9 years, with Q2 2025 value amounting to 75.04%.
- Sarepta Therapeutics' Gross Margin fell 126900.0% to 75.04% in Q2 2025 from the same period last year, while for Jun 2025 it was 90.8%, marking a year-over-year increase of 25100.0%. This contributed to the annual value of 83.22% for FY2024, which is 46900.0% down from last year.
- Sarepta Therapeutics' Gross Margin amounted to 75.04% in Q2 2025, which was down 126900.0% from 79.91% recorded in Q4 2024.
- In the past 5 years, Sarepta Therapeutics' Gross Margin ranged from a high of 88.87% in Q4 2023 and a low of 75.04% during Q2 2025
- For the 5-year period, Sarepta Therapeutics' Gross Margin averaged around 85.06%, with its median value being 86.19% (2023).
- As far as peak fluctuations go, Sarepta Therapeutics' Gross Margin surged by 61900bps in 2023, and later crashed by -126900bps in 2025.
- Quarter analysis of 5 years shows Sarepta Therapeutics' Gross Margin stood at 84.24% in 2021, then rose by 5bps to 88.08% in 2022, then grew by 1bps to 88.87% in 2023, then dropped by -10bps to 79.91% in 2024, then decreased by -6bps to 75.04% in 2025.
- Its last three reported values are 75.04% in Q2 2025, 79.91% for Q4 2024, and 80.37% during Q3 2024.